Search

Your search keyword '"Gu, Zili"' showing total 26 results
Start Over Author "Gu, Zili"
26 results on '"Gu, Zili"'

10. Tumor Pigmentation Does Not Affect Light-Activated Belzupacap Sarotalocan Treatment but Influences Macrophage Polarization in a Murine Melanoma Model

Author

Ma, Sen, primary, Huis in't Veld, Ruben V., additional, Hao, Yang, additional, Gu, Zili, additional, Rich, Cadmus, additional, Gelmi, Maria Chiara, additional, Mulder, Aat A., additional, van Veelen, Peter A., additional, Vu, T. Khanh H., additional, van Hall, Thorbald, additional, Ossendorp, Ferry A., additional, and Jager, Martine J., additional

Published
2024
Full Text
View/download PDF

25. Effective breast cancer therapy based on palmitic acid-loaded PLGA nanoparticles

Author

He, Yuanyuan, de Araújo Júnior, Raimundo Fernandes, Cavalcante, Rômulo S., Yu, Zhenfeng, Schomann, Timo, Gu, Zili, Eich, Christina, and Cruz, Luis J.

Abstract

Although new strategies for breast cancer treatment have yielded promising results, most drugs can lead to serious side effects when applied systemically. Doxorubicin (DOX), currently the most effective chemotherapeutic drug to treat breast cancer, is poorly selective towards tumor cells and treatment often leads to the development of drug resistance. Recent studies have indicated that several fatty acids (FAs) have beneficial effects on inhibiting tumorigenesis. The saturated FA palmitic acid (PA) showed anti-tumor activities in several types of cancer, as well as effective repolarization of M2 macrophages towards the anti-tumorigenic M1 phenotype. However, water insolubility and cellular impermeability limit the use of PA in vivo. To overcome these limitations, here, we encapsulated PA into a poly(d,l-lactic co-glycolic acid) (PLGA) nanoparticle (NP) platform, alone and in combination with DOX, to explore PA's potential as mono or combinational breast cancer therapy. Our results showed that PLGA-PA-DOX NPs and PLGA-PA NPs significantly reduced the viability and migratory capacity of breast cancer cells in vitro. In vivostudies in mice bearing mammary tumors demonstrated that PLGA-PA-NPs were as effective in reducing primary tumor growth and metastasis as NPs loaded with DOX, PA and DOX, or free DOX. At the molecular level, PLGA-PA NPs reduced the expression of genes associated with multi-drug resistance and inhibition of apoptosis, and induced apoptosis viaa caspase-3-independent pathway in breast cancer cells. In addition, immunohistochemical analysis of residual tumors showed a reduction in M2 macrophage content and infiltration of leukocytes after treatment of PLGA-PA NPs and PLGA-PA-DOX NPs, suggesting immunomodulatory properties of PA in the tumor microenvironment. In conclusion, the use of PA alone or in combination with DOX may represent a promising novel strategy for the treatment of breast cancer.

Published
2022
Full Text
View/download PDF

26. Hypericin-mediated photodynamic therapy for the treatment of cancer: a review.

Author

Dong X, Zeng Y, Zhang Z, Fu J, You L, He Y, Hao Y, Gu Z, Yu Z, Qu C, Yin X, Ni J, and Cruz LJ

Subjects
Antineoplastic Agents pharmacology, Humans, Perylene pharmacology, Photosensitizing Agents, Signal Transduction drug effects, Anthracenes pharmacology, Molecular Targeted Therapy methods, Neoplasms classification, Neoplasms metabolism, Neoplasms therapy, Perylene analogs & derivatives, Photochemotherapy methods
Abstract

Objectives: Hypericin is a polycyclic aromatic naphthodianthrone that occurs naturally. It is also an active ingredient in some species of the genus Hypericum. Emerging evidence suggests that hypericin has attracted great attention as a potential anticancer drug and exhibits remarkable antiproliferative effect upon irradiation on various tumour cells. This paper aims to summarise the anticancer effect and molecular mechanisms modulated by hypericin-medicated photodynamic therapy and its potential role in the cancer treatment., Key Findings: Hypericin-medicated photodynamic therapy could inhibit the proliferation of various tumour cells including bladder, colon, breast, cervical, glioma, leukaemia, hepatic, melanoma, lymphoma and lung cancers. The effect is primarily mediated by p38 mitogen-activated protein kinase (MAPK), JNK, PI3K, CCAAT-enhancer-binding protein homologous protein (CHOP)/TRIB3/Akt/mTOR, TRAIL/TRAIL-receptor, c-Met and Ephrin-Eph, the mitochondria and extrinsic signalling pathways. Furthermore, hypericin-medicated photodynamic therapy in conjunction with chemotherapeutic agents or targeted therapies is more effective in inhibiting the growth of tumour cells., Summary: During the past few decades, the anticancer properties of photoactivated hypericin have been extensively investigated. Hypericin-medicated photodynamic therapy can modulate a variety of proteins and genes and exhibit a great potential to be used as a therapeutic agent for various types of cancer., (© The Author(s) 2020. Published by Oxford University Press on behalf of Royal Pharmaceutical Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results